Libaccord
Supercooled Liquid Nitrogen for Treatment of Arrhythmia
Startup Pre-Funding Health Tech & Life Sciences Est. 2020
Total Raised
Undisclosed
Pre-Funding
Last Round
Undisclosed
Team
2
1-10 employees
Confidence
95/100
News
1
articles
Patents
1
About
Libaccord is the developer of an innovative device for treating ventricular and atrial arrhythmias using super-cooled liquid nitrogen. Based on the deepest possible ablation (transmural), the companys solution uses the novel clinical approach of scar homogenization to reduce procedure time and includes built-in ablation depth feedback to ensure performance and safety.
Classification
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target Customer
Healthcare & Life SciencesHealthcareProviders
Business Model
B2B
Tags
heart-failurecardiovascularhospitalscatheterstreatmentscardiologymedical-devices
News (1)
Jan 10, 2022 · www.haaretz.co.il
growth-positive
עם היד (הטכנולוגית) על הדופק
CustomersPartnersInvestment
Details
Product Stage
R&D
Employees
1-10
Exact Count
2
District
North District
Founded
2020
Locations
Haifa, Israel
Links
Admin
Last Update
Mar 2, 2025
Verified by
Yotam Maman
Claimed
Yes
Missing
video or image, funding rounds, markets, external profiles
Team (2)
Gregory Golovchiner
Co-founder
Founder
Yakov Nedlin
Co-founder & CTO
Founder
Internal
Created by
Yotam Maman (yotamm1988@gmail.com)
Created
2022-04-11T00:00:00.000Z
Last editor
Yotam Maman (yotamm1988@gmail.com)